Efficacy and safety of natalizumab extended interval dosing

被引：0
|
作者：
Zeineddine, Maya [1 ]
Ayyoubi, Nabil [1 ]
Tamim, Hani [2 ]
Nicolas, Johny [3 ]
Khoury, Samia [1 ]
Yamout, Bassem [1 ]
机构：
[1] Nehme & Therese Tohme Multiple Sclerosis Ctr, Beirut, Lebanon
[2] Amer Univ Beirut, Med Ctr, Clin Res Inst, Beirut, Lebanon
[3] Amer Univ Beirut, Med Ctr, Fac Med, Beirut, Lebanon
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
59
引用
收藏
页码：NP22 / NP23
页数：2
相关论文
共 50 条
  • [41] Population pharmacokinetic modeling of natalizumab efficacy using body weight as a classification factor for extended interval dosing.
    Muralidharan, K. K.
    Subramanyam, M.
    Evans, K.
    Steiner, D.
    Ho, P-R
    Amarante, D.
    Koendgen, H.
    Elkins, J.
    Nestorov, I.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 881 - 882
  • [42] Evaluating the Efficacy and Safety of 6-Week Extended Interval Dosing of Natalizumab Via a Prospective, Controlled, Randomized Phase 3b Study
    Cohen, Jeffrey A.
    Campbell, Nolan
    Wiendl, Heinz
    Foley, John
    Butzkueven, Helmut
    Ryerson, Lana Zhovtis
    Giovannoni, Gavin
    Arnold, Douglas L.
    Defer, Gilles
    Killestein, Joep
    Cutter, Gary R.
    Ren, Zheng
    Kasliwal, Rachna
    Stifano, Giuseppina
    Chang, Ih
    Ho, Pei-Ran
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 48 - 49
  • [43] Natalizumab extended interval dosing: what about wearing-off effect?
    Bernardes, Catarina
    Fernandes, Catarina
    Cunha, Carolina
    Batista, Sonia
    Nunes, Carla
    Macario, Maria do Carmo
    Sousa, Livia Maria
    Correia, Ines
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1010 - 1011
  • [44] Progressive Multifocal Leukoencephalopathy with Natalizumab Extended or Standard Interval Dosing in US and ROW
    Dsilva, L.
    McCarthy, K.
    Lyons, J.
    Cabigas, B.
    Campbell, N.
    Kong, G.
    Chin, W.
    Adams, B.
    Kuhelj, R.
    Singhal, P.
    Smirnakis, K.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 459 - 459
  • [45] MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study
    De Mercanti, Stefania Federica
    Signori, Alessio
    Cordioli, Cinzia
    Signoriello, Elisabetta
    Lus, Giacomo
    Bonavita, Simona
    Abbadessa, Gianmarco
    Lavorgna, Luigi
    Maniscalco, Giorgia Teresa
    Curti, Erica
    Lorefice, Lorena
    Cocco, Eleonora
    Nociti, Viviana
    Mirabella, Massimiliano
    Baroncini, Damiano
    Mataluni, Giorgia
    Landi, Doriana
    Petruzzo, Martina
    Lanzillo, Roberta
    Gandoglia, Ilaria
    Laroni, Alice
    Frangiamore, Rita
    Sartori, Arianna
    Cavalla, Paola
    Costantini, Gianfranco
    Capra, Ruggero
    Sormani, Maria Pia
    Clerico, Marinella
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 424
  • [46] Natalizumab extended interval dosing: what about wearing-off effect?
    Bernardes, Catarina
    Fernandes, Catarina
    Cunha, Carolina
    Nunes, Carla
    Macario, Carmo
    Sousa, Livia
    Batista, Sonia
    Correia, Ines
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2024, 458
  • [47] Long-term effectiveness of extended interval dosing of natalizumab in multiple sclerosis
    Ryerson, L. Zhovtis
    Lee, S.
    Bacon, T.
    Toth, E.
    Chinea, R.
    Gragui, D.
    Kister, I.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 358 - 359
  • [48] Influence of personalized extended interval dosing on the natalizumab wearing-off effect
    Toorop, Alyssa
    Wessels, Mark
    Gelissen, Liza
    Hoitsma, E.
    Zeinstra, Esther
    van Rooij, Luuk
    van Munster, Caspar
    Vennegoor, Anke
    Mostert, Jop
    Wokke, Beatrijs
    Kalkers, Nynke. F.
    Hoogervorst, E. L. J.
    van Eijk, Jeroen
    Roosendaal, Christiaan
    Kragt, Jolijn
    Eurelings, Marijke
    van Genugten, Jessie
    Nielsen, Jessica
    Sinnige, Okke
    Kloosterziel, Mark
    Arnoldus, Edo P. J.
    van Dijk, Gert
    Bouvy, Willem
    Strijbis, Eva
    van Oosten, Bob
    Brigit, de Jong
    Lissenberg-Witte, Birgit
    Rispens, Theo
    Uitdehaag, Bernard
    Killestein, Joep
    van Kempen, Zoe
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 387 - 388
  • [49] One year of natalizumab extended interval dosing: what have we learned
    Bernardes, C.
    Fernandes, C.
    Correia, I.
    Nunes, C.
    Macario, C.
    Batista, S.
    Sousa, L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 652 - 652
  • [50] Personalized extended interval dosing of natalizumab in multiple sclerosis: a prospective multicenter trial
    van Kempen, Z.
    Hoogervorst, E.
    Kalkers, N.
    Mostert, J.
    Lissenberg-Witte, B.
    de Vries, A.
    ten Brinke, A.
    van Oosten, B.
    Barkhof, F.
    Wattjes, M.
    Teunissen, C.
    Uitdehaag, B.
    Rispens, T.
    Killestein, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 735 - 736
12345